Generalized Additive Model demonstrates fluoroquinolone use/resistance relationships for Staphylococcus aureus

被引：15

作者：

Berger P. ^{[1
]}

Pascal L. ^{[3
]}

Sartor C. ^{[2
]}

Delorme J. ^{[4
]}

Monge P. ^{[5
]}

Ragon C.P. ^{[6
]}

Charbit M. ^{[7
]}

Sambuc R. ^{[1
]}

Drancourt M. ^{[2
,8
]}

机构：

[1] Lab. d'Eval. Hospitaliere - M., Faculté de Médecine, Marseilles

[2] Comite Lutte Contre Les I., Hôtel Dieu, Marseilles

[3] Dépt. d'Info. Médicale, Hôpital de la Conception, Marseilles

[4] Pharmacie Hôpital de la Timone, Marseilles

[5] Pharm. Hôp. de la Conception, Marseilles

[6] Pharm. Hop. de Sainte-Marguerite, Marseilles

[7] Pharmacie Hôpital Nord, Marseilles

[8] Unité des Rickettsies, Faculté de Médecine, 13385 Marseille Cedex 05, 27, Boulevard Jean Moulin

来源：

European Journal of Epidemiology | 2004年 / 19卷 / 5期

关键词：

Anti-infective agents; Fluoroquinolone/drug resistance; Microbial/Generalized Additive Model/Staphylococcus aureus;

D O I：

10.1023/B:EJEP.0000027348.92979.94

中图分类号：

学科分类号：

摘要：

Mathematical models currently used to study the relationship between the prevalence of the resistance to an antibiotic and the amount of drug may not be adequate because they do not integrate temporal and area analyses simultaneously. Furthermore, the forms of such relationship are unknown. We applied the Generalized Additive Model (GAM) to study fluoroquinolone use and the incidence of fluoroquinolone-resistance in Staphylococcus aureus in our institution over a 3-year period. Overall institution and individual hospital unit-restricted analyses were performed. Relative risk (RR) observed for increasing fluoroquinolone use with a 4-month lag from the 25th percentile to the 75th percentile was 1.27 (95% CI: 1.13-1.42). In the surgery units, RR was 1.23 (95% CI: 1.01-1.50) for fluoroquinolone use with a 2-months lag. GAM enabled us to observe for the first time a significant temporal relationship between fluoroquinolone use and the incidence of fluoroquinolone-resistant nosocomial S. aureus isolates.

引用

页码：453 / 460

页数：7

共 45 条

[1]

Cohen M.L., Changing patterns of infectious disease, Nature, 406, pp. 762-767, (2000)

[2]

Greenwood D., Preserving the miracle of antibiotics, Lancet, 345, (1995)

[3]

Wadman M., Group urges survey of antibiotics in animals, Nature, 409, (2001)

[4]

Diekema D.J., Pfaller M.A., Schmitz F.J., Et al., Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999, Clin Infect Dis, 32, 2 SUPPL., (2001)

[5]

Fluit A.C., Jones M.E., Schmitz F.J., Acar J., Gupta R., Verhoef J., Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998, Clin Infect Dis, 30, pp. 454-460, (2000)

[6]

Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P., Nosocomial bloodstream infections in United States hospitals: A 3-year analysis, Clin Infect Dis, 29, pp. 239-244, (1999)

[7]

CDR Weekly, 7, (1997)

[8]

Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin, MMWR, 46, pp. 626-635, (1997)

[9]

Hanberger H., Diekema D., Fluit A., Et al., Surveillance of antibiotic resistance in European ICUs, J Hosp Infect, 48, pp. 161-176, (2001)

[10]

Vincent J.L., Microbial resistance: Lessons from the EPIC study. European Prevalence of Infection, Intensive Care Med, 26, 1 SUPPL., (2000)

← 1 2 3 4 5 →